NCT02048319View on ClinicalTrials.gov

Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Hepatic Cysts

PHASE3CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

April 30, 2016

Conditions
Symptomatic Dominant Liver Cyst
Interventions
DRUG

Pasireotide LAR 60 mg

Pasireotide long acting release, intramuscular injection

PROCEDURE

Aspiration sclerotherapy

Percutaneous drainage of the hepatic cyst with subsequent ethanol instillation

DRUG

Placebo

Saline solution, injected as placebo

Trial Locations (1)

6500 HB

Radboud University Nijmegen Medical Center; Department of Gastroenterology & Hepatology, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

NCT02048319 - Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Hepatic Cysts | Biotech Hunter | Biotech Hunter